Default company panoramic image
Logo

Amal Therapeutics SA

Amal Therapeutics SA is a privately-held Swiss biotech start-up company which is a spin-off from the University of Geneva. Amal was incorporated on the 3rd o...

Company Summary

Amal Therapeutics SA is a privately-held Swiss biotech start-up company which is a spin-off from the University of Geneva. Amal was incorporated on the 3rd of September 2012. Its main objective is to develop and progress a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed proteins.

Team

  • Default avatar
    Madiha Derouazi
    Mrs

    Madiha Derouazi holds a PhD in Biotechnology from the EPFL, Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.
    Madiha Derouazi has been working on vector engineering and therapeutic cancer vaccines for over 8 years, working at Pfizer, the EPFL and the CNRS (France) . As Project leader since 2009 at the Laboratory of Tumor Immunology of the University of Geneva, she designed and characteriz

  • Default avatar
    Nasrine Borbor
    Mrs

    Nasrine Borbor Ghadjar studied Law at the University of Geneva. From 1986 to 1992, Nasrine Borbor Ghadjar worked as a legal and tax Consultant for Deloitte and Price Waterhouse Coopers. Over the last 20 years, she has built up strong experience in Corporate law, Swiss and international tax laws, labour law, human resources and accounting by running her own independent businesses.